Urticaria
MONDO:0005492A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.
Also known as: hives, urticaria, urticaria (disease), Urticarias
164 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Teens with rare swelling disorder get new drug tested
Disease control CompletedThis study looked at how a new oral medication (sebetralstat) works in the bodies of 11 teenagers aged 12 to 17 with hereditary angioedema (HAE) types I or II. The goal was to measure drug levels and timing in the blood. All participants were already in a larger HAE trial. The st…
Phase: PHASE3 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New pill shows promise for controlling rare swelling disorder
Disease control CompletedThis study looked at the long-term safety of an oral medication called KVD900 for treating swelling attacks in people with hereditary angioedema (HAE) types I or II. The trial enrolled 145 adolescents and adults who had already completed a previous study. Participants took KVD900…
Phase: PHASE3 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New shot could stop painful swelling attacks in kids
Disease control CompletedThis study tested a drug called Garadacimab in 22 children aged 2 to 11 with hereditary angioedema, a condition that causes sudden, painful swelling. The drug is given as a shot under the skin to prevent attacks. The study looked at safety and how well it works. It has already be…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New injection shows promise for long-term prevention of rare swelling disorder
Disease control CompletedThis study tested the long-term safety and effectiveness of garadacimab, a monthly injection, for preventing attacks of hereditary angioedema (HAE) — a rare condition causing severe swelling. 171 people aged 12 and older who had frequent HAE attacks took part. The goal was to see…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Molecular map may guide treatment for mysterious inflammatory illnesses
Disease control CompletedThis study tested whether analyzing a patient's DNA and RNA could help doctors pick the right drug for inflammatory diseases that don't fit standard categories. 32 adults with at least two affected organs (including skin) received one of six targeted therapies based on their mole…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New pill could stop hives from scratching or cold
Disease control CompletedThis phase 2a trial tested an oral drug called EVO756 in 30 adults with chronic inducible urticaria, a condition where physical triggers like scratching or cold cause hives. The study aimed to see if the drug is safe and can reduce wheals. Results are not yet available.
Phase: PHASE2 • Sponsor: Evommune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug navenibart aims to tame hereditary swelling attacks
Disease control CompletedThis early trial tested a new drug called navenibart in 29 people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. Participants received one or two doses of the drug to check its safety and how well it might reduce attacks. The study is …
Phase: PHASE1, PHASE2 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug shows promise for controlling rare swelling disorder
Disease control CompletedThis study tested the long-term safety and effectiveness of donidalorsen, an injectable drug, in 20 people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. Participants received different doses over 64 weeks. The main goal was to check f…
Phase: PHASE2 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Real-world study shows lanadelumab keeps HAE attacks at bay for many patients
Disease control CompletedThis study followed 48 people with hereditary angioedema (HAE) in Poland who were taking lanadelumab as part of a national drug program. Researchers tracked how many participants remained attack-free over 24 months, how many attacks still needed rescue treatment, and the severity…
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill could tame stubborn hives when antihistamines fail
Disease control CompletedThis phase 2 trial tested an oral drug called povorcitinib in 136 adults with chronic spontaneous urticaria (hives and itching lasting months) that standard antihistamines couldn't control. Participants took either povorcitinib or a placebo for 12 weeks to see if the drug reduced…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Real-World data reveals how HAE drugs perform in chinese patients
Disease control CompletedThis study reviewed medical records of 115 Chinese people with hereditary angioedema (HAE) to see how well two approved drugs work in real life. One drug, lanadelumab, is used to prevent attacks, and the other, icatibant, treats sudden attacks. Researchers measured attack rates a…
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New shot could stop chronic hives when antihistamines fail
Disease control CompletedThis Phase 2 trial tested a new injectable drug called LP-003 in 202 adults with chronic spontaneous urticaria (long-lasting hives and itching) that standard antihistamines couldn't control. The study compared LP-003 to a placebo and to an existing drug (omalizumab) to see if it …
Phase: PHASE2 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for kids with stubborn hives: dupixent studied
Disease control CompletedThis study tested the drug dupilumab (Dupixent) in 15 children aged 2 to 12 who have chronic spontaneous urticaria (CSU), also known as long-lasting hives, that didn't get better with antihistamines. The main goals were to check how the drug behaves in the body and to see if it's…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New pill could stop swelling attacks in hereditary angioedema
Disease control CompletedThis study tested an oral medication called deucrictibant for quickly treating attacks of hereditary angioedema (HAE), a condition causing sudden, painful swelling. The trial involved 134 adolescents and adults with HAE types 1, 2, or 3. Participants took either the drug or a pla…
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New daily pill could stop painful swelling attacks in rare disease
Disease control CompletedThis study tested an oral drug called BCX4161 to prevent attacks of hereditary angioedema (HAE), a condition that causes sudden, painful swelling. Over 12 weeks, 110 adults with HAE took either a low dose, high dose, or placebo pill. Researchers tracked how many swelling attacks …
Phase: PHASE2, PHASE3 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New shot could tame stubborn hives that antihistamines Can't stop
Disease control CompletedThis Phase 2 study tested a drug called barzolvolimab (CDX-0159) in 196 adults with chronic inducible urticaria—hives triggered by cold or scratching—that persist despite antihistamines. Participants received either the drug or a placebo as a shot under the skin. The main goal wa…
Phase: PHASE2 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug for stubborn hives passes blood pressure check in phase 3 trial
Disease control CompletedThis study tested a drug called remibrutinib in 144 adults with chronic spontaneous urticaria (hives lasting over 6 months) that standard antihistamines couldn't control. Participants took a 25 mg tablet twice daily for up to 12 weeks. The main goal was to see if the drug affecte…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New biosimilar aims to tame stubborn hives at lower cost
Disease control CompletedThis completed Phase 3 trial tested whether TEV-45779, a biosimilar of the drug omalizumab (XOLAIR), works as well as the original for people with chronic hives that don't improve with antihistamines. 608 participants received either the biosimilar or XOLAIR. The main goal was to…
Phase: PHASE3 • Sponsor: Teva Pharmaceuticals USA • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New shot could stop cold hives
Disease control CompletedThis study tested dupilumab, an injectable drug, in 82 people with cold urticaria (hives triggered by cold) who still had symptoms despite taking antihistamines. The goal was to see if dupilumab could prevent hives after an ice cube test and improve quality of life. Participants …
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 16:22 UTC
-
Real-World data shows lanadelumab cuts HAE attacks over three years
Disease control CompletedThis study followed 140 people with hereditary angioedema (HAE) who were already taking lanadelumab. Researchers compared the number of swelling attacks during treatment to the number before starting the drug. Participants reported their symptoms via a smartphone app and during c…
Sponsor: Shire • Aim: Disease control
Last updated Jun 26, 2026 13:06 UTC
-
New rapid test for infection and inflammation put to the test
Diagnosis CompletedThis study looked at how well a new, quick finger-prick test (LumiraDx CRP) measures CRP levels compared to a standard lab test. CRP is a marker of infection, inflammation, or tissue injury. 79 adults with symptoms of these conditions took part. The goal was to see if the new tes…
Sponsor: LumiraDx UK Limited • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
Smartphone AI could help doctors monitor skin disease remotely
Diagnosis CompletedThis study tested whether an artificial intelligence tool called Legit Health Plus can help doctors track the severity of chronic skin conditions like acne, psoriasis, and eczema from a distance. 160 participants used a smartphone app for 6 months to take photos of their skin and…
Sponsor: AI Labs Group S.L • Aim: Diagnosis
Last updated Jun 27, 2026 11:03 UTC
-
AI boosts skin diagnosis accuracy in small trial
Diagnosis CompletedThis completed study tested whether an AI device could help 16 doctors (10 general practitioners and 6 dermatologists) more accurately diagnose 13 different skin conditions, including melanoma, psoriasis, and acne. The doctors reviewed 29 medical images, first giving a diagnosis …
Sponsor: AI Labs Group S.L • Aim: Diagnosis
Last updated Jun 27, 2026 09:07 UTC
-
AI boosts skin diagnosis accuracy for GPs in small trial
Diagnosis CompletedThis study tested whether an artificial intelligence (AI) tool could help primary care doctors diagnose skin conditions more accurately. Nine doctors reviewed 30 images of various skin problems, first giving their own diagnosis and then a final diagnosis after seeing the AI's sug…
Sponsor: AI Labs Group S.L • Aim: Diagnosis
Last updated Jun 27, 2026 09:07 UTC
-
New PET tracer aims to light up hidden infections
Diagnosis CompletedThis early study tested a new radioactive tracer called 18F-FDS in 16 people with suspected bacterial or fungal infections. The tracer is designed to light up infection sites on PET/CT scans, helping doctors see exactly where an infection is. The goal was to check how the tracer …
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
New hope for chronic hives sufferers: experimental drug EVO756 under study
Symptom relief CompletedThis study tests an experimental drug called EVO756 in 160 adults with moderate to severe chronic spontaneous urticaria (CSU), also known as chronic hives. Participants must have had hives for at least 3 months and not gotten enough relief from standard antihistamines. The goal i…
Phase: PHASE2 • Sponsor: Evommune, Inc. • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
New pill could tame stubborn hives
Symptom relief CompletedThis early-stage trial tested an experimental oral drug called BGB-16673 in 34 adults with chronic spontaneous urticaria (CSU), a condition causing persistent hives and itching. The study was double-blind and placebo-controlled, meaning neither patients nor doctors knew who got t…
Phase: PHASE1 • Sponsor: BeiGene • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New tablet shows promise for chronic hives in small study
Symptom relief CompletedThis study tested a daily tablet called NatureU Histra Disslove in 19 adults with chronic hives. Participants took one tablet before a main meal for 28 days. The study measured how well the tablet controlled hives, reduced symptoms, and improved quality of life. Results showed ch…
Phase: NA • Sponsor: OmniSolutions Laboratory Holdings Limited • Aim: Symptom relief
Last updated Jun 27, 2026 12:39 UTC
-
DIY bandage change: could self-dressing heal foot ulcers just as well?
Symptom relief CompletedThis study tested whether people with diabetic foot ulcers can safely change their own dressings compared to having a nurse do it. Sixty adults with mild to moderate ulcers were randomly assigned to either self-dressing or nurse-led dressing. The researchers tracked healing time,…
Phase: NA • Sponsor: Ain Shams University • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Nasal spray may offer fast hives relief without needles
Symptom relief CompletedThis study tested a single dose of a nasal spray called ARS-1 (intranasal epinephrine) in 21 adults who get frequent hives and itching. The goal was to see if the spray works faster and better than a placebo at reducing itch and hive scores during flare-ups. Participants were mon…
Phase: PHASE2 • Sponsor: ARS Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
Insulin dressing shows promise for diabetic foot ulcers
Symptom relief CompletedThis study tested whether applying insulin directly to diabetic foot ulcers helps them heal better than standard saline dressings. Thirty adults with diabetes and foot ulcers participated. Researchers measured healing rates and whether surgery was needed.
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
New hope for teens with stubborn hives: xolair shows promise
Symptom relief CompletedThis study looked at whether Xolair (omalizumab) is safe and works for Chinese teenagers with chronic spontaneous urticaria (long-term hives and itching) that doesn't get better with standard antihistamines. 55 teens took part, receiving Xolair for 12 weeks, followed by 4 weeks o…
Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
Which pill stops the itch? new study pits bilastine against levocetirizine for hives
Symptom relief CompletedThis study tested two different antihistamine treatments in 60 adults with chronic hives (itchy welts that keep coming back). One group took a higher dose of bilastine, the other took a mix of bilastine and levocetirizine. The goal was to see which approach better reduces itching…
Phase: NA • Sponsor: Derma Techno Pakistan • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
New hope for kids with rare swelling disorder: sebetralstat shows promise
Symptom relief CompletedThis study tested a drug called sebetralstat in 36 children aged 2 to 11 with hereditary angioedema (HAE) types I or II, a condition that causes sudden, painful swelling. The goal was to see if the drug is safe and how well it works to relieve attacks. The trial was open-label, m…
Phase: PHASE3 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
New drug shows promise for teens with stubborn hives
Symptom relief CompletedThis study tested a drug called ligelizumab in 49 teenagers aged 12 to 17 who had chronic hives (itchy welts) that didn't get better with standard allergy pills. The goal was to see if adding ligelizumab to their current treatment could reduce the number and severity of hives. Pa…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
New drug offers hope for rare swelling disorder patients
Symptom relief CompletedThis study tested a drug called icatibant (Icanticure) in 5 adults with a rare condition that causes sudden, painful swelling attacks. The goal was to see how quickly the drug relieved symptoms and if it was safe. Participants received the injection for free during an acute attac…
Phase: PHASE4 • Sponsor: Nang Kuang Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
New pill could stop painful swelling attacks in rare disease
Symptom relief CompletedThis study tested an oral medication called deucrictibant for quickly relieving swelling and pain attacks in people with hereditary angioedema (HAE) types I and II. 74 adults received either one of three doses of the drug or a placebo during an attack. The main goal was to see if…
Phase: PHASE2 • Sponsor: Pharvaris Netherlands B.V. • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Firazyr tested in kids with rare swelling disorder
Symptom relief CompletedThis study in Japan looked at 32 children (ages 2 to under 18) with hereditary angioedema who received Firazyr injections for acute attacks. Researchers tracked side effects and how quickly symptoms resolved over 3 months. The goal was to gather real-world safety and effectivenes…
Sponsor: Takeda • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
ER hives study: do steroids really help?
Symptom relief CompletedThis study tested whether giving a steroid (cortancyl) along with an antihistamine (levocetirizine) is better than the antihistamine alone for treating sudden hives in the emergency department. 137 adults with acute urticaria (with or without mild angioedema) were enrolled. The m…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Study explores how family and friends impact caregiver health
Knowledge-focused CompletedThis completed study looked at how the social networks of caregivers affect their stress and health when caring for someone with an inherited disease. Researchers surveyed over 680 participants, including family members and formal caregivers, to understand caregiving burden and s…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
New hives drug candidate takes first step in human safety trial
Knowledge-focused CompletedThis early-stage study tests a new oral drug called HRS-3095 in 66 healthy adults aged 18-55. The main goal is to check safety and how the body processes the drug, not to treat any disease. Results will help design future studies for chronic spontaneous urticaria (long-term hives…
Phase: PHASE1 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
HAE patients and caregivers speak out: the hidden costs of On-Demand treatment
Knowledge-focused CompletedThis completed French survey of 300 hereditary angioedema (HAE) patients and their caregivers aimed to understand the challenges of using on-demand treatments for HAE attacks. Researchers collected data on attack frequency, severity, treatment delays, hospitalizations, and the fi…
Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Real-World data reveals omalizumab prescribing patterns for chronic hives in china
Knowledge-focused CompletedThis study examined how the drug omalizumab is prescribed in real-world practice for adults with chronic urticaria (long-term hives) in China. Researchers analyzed electronic health records from over 3,400 patients to see what doses were commonly used. The goal was to understand …
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Scientists probe genetic roots of Cold-Triggered hives
Knowledge-focused CompletedThis study looks at why some people develop hives from physical triggers like cold, pressure, or sunlight. Researchers will test participants' skin reactions and collect blood and genetic samples to understand the role of immune cells and genes. The goal is to uncover the underly…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Vibrating platforms change reflex timing, small study finds
Knowledge-focused CompletedThis study looked at how standing on a vibrating platform affects spinal reflexes in 15 healthy adults. Participants stood in different positions with or without vibration while researchers measured electrical signals from a leg muscle. The goal was to understand how vibration ch…
Phase: NA • Sponsor: Istanbul Physical Medicine Rehabilitation Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Scientists probe gene activity in rare swelling disorder
Knowledge-focused CompletedThis study looked at gene activity in immune cells from 30 people with hereditary angioedema and healthy volunteers. The goal was to see if certain receptors on monocytes are linked to inflammation and blood vessel problems. No treatment was given; the study was purely observatio…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
AI could cut skin specialist wait times, study hints
Knowledge-focused CompletedThis study tested an artificial intelligence algorithm designed to help primary care doctors decide whether a patient with a skin condition really needs to see a dermatologist. Researchers enrolled 200 adults with skin problems and had their doctors take photos of the affected ar…
Sponsor: AI Labs Group S.L • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Real-World data on HAE attack treatment collected in completed study
Knowledge-focused CompletedThis study followed 88 people with hereditary angioedema (HAE) types I or II who already use icatibant for sudden attacks. Participants filled out diaries for 48 hours after each attack to report symptom changes, severity, and anxiety levels. The goal was to gather real-world inf…
Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Real-world study tracks xolair dose bumps for stubborn hives
Knowledge-focused CompletedThis study looked at how often doctors increase the dose or give Xolair more frequently for people with chronic hives. Researchers followed 163 adults for 3 months to see how many needed a stronger treatment plan. The goal was to understand real-world use, not to test a new drug.
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Pandemic's hidden toll: skin allergies surge among healthcare workers
Knowledge-focused CompletedThis study examined how the COVID-19 pandemic impacted skin allergy visits among healthcare workers. Researchers analyzed records from 341 healthcare workers who visited skin clinics before and after the pandemic. The goal was to understand if increased use of masks, gloves, and …
Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
New biologic LP-003 takes first step in human safety trial
Knowledge-focused CompletedThis study tested the safety and tolerability of a new biologic drug called LP-003 in 60 healthy volunteers. The drug is being developed for chronic spontaneous urticaria (long-lasting hives). The trial gave single or multiple doses of LP-003 or a placebo by IV to see how the bod…
Phase: PHASE1 • Sponsor: Longbio Pharma • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Tiny study probes whether viruses trigger stubborn hives
Knowledge-focused CompletedThis completed study took blood samples from 10 people with chronic spontaneous urticaria (long-lasting hives) to check for viral particles. The goal was to see if hidden viruses might be involved in causing the condition. Because it is a small observational study, it can only su…
Sponsor: HaEmek Medical Center, Israel • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:04 UTC